Clinically Meaningful Responses to Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications in the Randomized, Placebo-Controlled FOCUS Study

被引：0
|
作者：
Spierings, Egilius L. H. [1 ]
Ning, Xiaoping [2 ]
Galic, Maja [3 ]
Cohen, Joshua M. [2 ]
Yang, Ronghua [2 ]
机构：
[1] Medvadis Res Corp, Watertown, MA USA
[2] Teva Pharmaceut Ind, Frazer, PA USA
[3] Teva Pharmaceut, Amsterdam, Netherlands
来源：
ANNALS OF NEUROLOGY | 2019年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
M195
引用
收藏
页码：S168 / S168
页数：1
相关论文
共 50 条
  • [21] Reversion from chronic to episodic migraine and clinically meaningful responses to fremanezumab in patients with inadequate response to 2-4 classes of migraine preventive medications
    Ashina, M.
    Ning, X.
    Galic, M.
    Cohen, J. M.
    Ramirez-Campos, V.
    Yang, R.
    Ailani, J.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [22] Efficacy of Fremanezumab in Migraine Patients with Medication Overuse and Documented Inadequate Response to 2-4 Migraine Preventive Medication Classes: Subgroup Analysis of the Randomized, Placebo-controlled FOCUS Study
    Silberstein, Stephen
    Cohen, Joshua M.
    Ramirez-Campos, Verena
    Yang, Ronghua
    Galic, Maja
    Ning, Xiaoping
    Jann, Adelene
    NEUROLOGY, 2020, 94 (15)
  • [23] Efficacy of Fremanezumab in Migraine Patients with Medication Overuse and Documented Inadequate Response to 2-4 Migraine Preventive Medication Classes: Subgroup Analysis of the Randomized, Placebo-Controlled FOCUS Study
    Silberstein, Stephen
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Yang, Ronghua
    Galic, Maja
    Ning, Xiaoping
    Jann, Adelene
    ANNALS OF NEUROLOGY, 2020, 88 : S157 - S158
  • [24] Impact of fremanezumab on headache-related disability in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive medications in the multicentre, randomised, placebo-controlled FOCUS study
    Ashina, Messoud
    Ferrari, Michel D.
    Ning, Xiaoping
    Galic, Maja
    Cohen, Joshua M.
    Yang, Ronghua
    CEPHALALGIA, 2019, 39 : 224 - 225
  • [25] Impact of fremanezumab on migraine-associated symptoms in patients with documented inadequate response to 2-4 classes of migraine preventive medications in the international, multicentre, randomised, placebo-controlled FOCUS study
    McAllister, Peter
    Ning, Xiaoping
    Galic, Maja
    Cohen, Joshua M.
    Yang, Ronghua
    CEPHALALGIA, 2019, 39 : 223 - 223
  • [26] Work productivity and activity impairment in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive medications in the international, multicentre, randomised, placebo-controlled FOCUS study of fremanezumab
    Lipton, R. B.
    Pozo Rosich, P.
    Ning, X.
    Galic, M.
    Cohen, J. M.
    Yang, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 799 - 800
  • [27] Efficacy of fremanezumab in migraine patients with medication overuse and documented inadequate response to 2-4 migraine preventive medications: subgroup analysis of the randomised, placebo-controlled FOCUS study
    Silberstein, Stephen
    Cohen, Joshua M.
    Ramirez-Campos, Verena
    Yang, Ronghua
    Galic, Maja
    Ning, Xiaoping
    Jann, Adelene
    CEPHALALGIA, 2019, 39 : 226 - 227
  • [28] Impact of fremanezumab on headache-related disability in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive medications in the international, multicentre, randomised, placebo-controlled FOCUS study
    Ashina, M.
    Ferrari, M. D.
    Ning, X.
    Galic, M.
    Cohen, J. M.
    Yang, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 137 - 137
  • [29] Impact of fremanezumab on acute headache medication use in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive medications in the international, multicentre, randomised, placebo-controlled FOCUS study
    Diener, H-C.
    Ning, X.
    Galic, M.
    Cohen, J. M.
    Yang, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 426 - 427
  • [30] Efficacy, clinically meaningful responses, and impact on acute headache medication use with fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive treatments: results of the international, multicentre, randomised, placebo-controlled FOCUS study
    Ferrari, Michel D.
    Diener, Hans Christoph
    Spierings, Egilius L. H.
    Ning, Xiaoping
    Galic, Maja
    Cohen, Joshua M.
    Yang, Ronghua
    Ashina, Messoud
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (SUPPL 1):
12345